New targets for the treatment of follicular lymphoma.
The last two decades have witnessed striking advances in our understanding of the biological factors underlying the development of Follicular lymphoma (FL). Development of newer treatment approaches have improved the outlook for many individuals with these disorders; however, with these advances come new questions. Given the long-term survival of patients with FL, drugs with favourable side-effect profile and minimal long-term risks are desired. FL is incurable with current treatment modalities. It often runs an indolent course with multiple relapses and progressively shorter intervals of remission. The identification of new targets and development of novel targeted therapies is imperative to exploit the biology of FL while inherently preventing relapse and prolonging survival. This review summarizes the growing body of knowledge regarding novel therapeutic targets, enabling the concept of individualized targeted therapy for the treatment of FL.
Tageja
Nishant
N
Department of Internal Medicine, Division of Hematology/Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Padheye
Subhash
S
Dandawate
Prasad
P
Al-Katib
Ayad
A
Mohammad
Ramzi M
RM
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008495:Medical Oncology / Q000639:trends; D008954:Models, Biological; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D000970:Antineoplastic Agents